USFDA issues warning letter to Cipla for Goa manufacturing facility

NEW DELHI, Feb 26: Drug firm Cipla Ltd on Wednesday said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.
“Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA,” Cipla Ltd said in a regulatory filing.
The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.